Oncolytic vaccinia virus synergizes with irinotecan in colorectal cancer

Molecular Oncology

Volumn 9, Issue 8, 2015, Pages 1539-1552

  Ottolino Perry, Kathryn ^a,b   Acuna, Sergio A ^b   Angarita, Fernando A ^a,b   Sellers, Clara ^b   Zerhouni, Siham ^a,b   Tang, Nan ^b   McCart, J Andrea ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Chemotherapy; Combination therapy; Double deleted vaccinia virus; Metastatic colorectal cancer; Oncolytic virotherapy; Orthotopic tumour model

Indexed keywords

FIRTECAN; IRINOTECAN; ONCOLYTIC VACCINIA VIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; OXALIPLATIN; PLATINUM COMPLEX;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CANCER PATIENT; CELL CYCLE S PHASE; CELL INFILTRATION; CELL KILLING; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; LONG TERM SURVIVAL; MONOTHERAPY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CHLOROCEBUS AETHIOPS; COLORECTAL NEOPLASMS; HT 29 CELL LINE; MULTIMODALITY CANCER THERAPY; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; PATHOLOGY; VACCINIA VIRUS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DRUG SYNERGISM; FEMALE; HT29 CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; ORGANOPLATINUM COMPOUNDS; VACCINIA VIRUS;

EID: 84942195374     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2015.04.009     Document Type: Article

References (53)

1. Acuna S.A., Ottolino-Perry K., Cako B., Tang N., Angarita F.A., McCart J.A. Oncolytic vaccinia virus as an adjuvant treatment to cytoreductive surgery for malignant peritoneal mesothelioma. Ann. Surg. Oncol. 2014, 21:2259-2266.
2. Advani S.J., Buckel L., Chen N.G., Scanderbeg D.J., Geissinger U., Zhang Q., Yu Y.A., Aguilar R.J., Mundt A.J., Szalay A.A. Preferential replication of systemically delivered oncolytic vaccinia virus in focally irradiated glioma xenografts. Clin. Cancer Res. 2012, 18:2579-2590.
3. Breitbach C.J., De Silva N.S., Falls T.J., Aladl U., Evgin L., Paterson J., Sun Y.Y., Roy D.G., Rintoul J.L., Daneshmand M., Parato K., Stanford M.M., Lichty B.D., Fenster A., Kirn D., Atkins H., Bell J.C. Targeting tumor vasculature with an oncolytic virus. Mol. Ther. 2011, 19:886-894.
4. Breitbach C.J., Paterson J.M., Lemay C.G., Falls T.J., McGuire A., Parato K.A., Stojdl D.F., Daneshmand M., Speth K., Kirn D., McCart J.A., Atkins H., Bell J.C. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol. Ther. 2007, 15:1686-1693.
5. Brenner H., Kloor M., Pox C.P. Colorectal cancer. Lancet 2014, 383:1490-1502.
6. Chalikonda S., Kivlen M.H., O'Malley M.E., Eric Dong X.D., McCart J.A., Gorry M.C., Yin X.Y., Brown C.K., Zeh H.J., Guo Z.S., Bartlett D.L. Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene. Cancer Gene Ther. 2008, 15:115-125.
7. Cherubini G., Kallin C., Mozetic A., Hammaren-Busch K., Muller H., Lemoine N.R., Hallden G. The oncolytic adenovirus Adδδ enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models. Gene Ther. 2011, 18:1157-1165.
8. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
9. de Magalhaes J.C., Andrade A.A., Silva P.N., Sousa L.P., Ropert C., Ferreira P.C., Kroon E.G., Gazzinelli R.T., Bonjardim C.A. A mitogenic signal triggered at an early stage of vaccinia virus infection: implication of MEK/ERK and protein kinase A in virus multiplication. J. Biol. Chem. 2001, 276:38353-38360.
10. Ehrig K., Kilinc M.O., Chen N.G., Stritzker J., Buckel L., Zhang Q., Szalay A.A. Growth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68. J. Transl. Med. 2013, 11:79. 5876-11-79.
11. Gholami S., Chen C.H., Belin L.J., Lou E., Fujisawa S., Antonacci C., Carew A., Chen N.G., De Brot M., Zanzonico P.B., Szalay A.A., Fong Y. Vaccinia virus GLV-1h153 is a novel agent for detection and effective local control of positive surgical margins for breast cancer. Breast Cancer Res. 2013, 15:R26.
12. Goldwasser F., Gross-Goupil M., Tigaud J.M., Di Palma M., Marceau-Suissa J., Wasserman E., Yovine A., Misset J.L., Cvitkovic E. Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients. Ann. Oncol. 2000, 11:1463-1470.
13. Greiner S., Humrich J.Y., Thuman P., Sauter B., Schuler G., Jenne L. The highly attenuated vaccinia virus strain modified virus Ankara induces apoptosis in melanoma cells and allows bystander dendritic cells to generate a potent anti-tumoral immunity. Clin. Exp. Immunol. 2006, 146:344-353.
14. Guo Y., Lu P., Farrell E., Zhang X., Weller P., Monshouwer M., Wang J., Liao G., Zhang Z., Hu S., Allard J., Shafer S., Usuka J., Peltz G. In silico and in vitro pharmacogenetic analysis in mice. Proc. Natl. Acad. Sci. USA 2007, 104:17735-17740.
15. Gupta M., Zhu C.X., Tse-Dinh Y.C. An engineered mutant of vaccinia virus DNA topoisomerase I is sensitive to the anti-cancer drug camptothecin. J. Biol. Chem. 1992, 267:24177-24180.
16. Gutermann A., Mayer E., von Dehn-Rothfelser K., Breidenstein C., Weber M., Muench M., Gungor D., Suehnel J., Moebius U., Lechmann M. Efficacy of oncolytic herpesvirus NV1020 can be enhanced by combination with chemotherapeutics in colon carcinoma cells. Hum. Gene Ther. 2006, 17:1241-1253.
17. Halama N., Michel S., Kloor M., Zoernig I., Benner A., Spille A., Pommerencke T., von Knebel D.M., Folprecht G., Luber B., Feyen N., Martens U.M., Beckhove P., Gnjatic S., Schirmacher P., Herpel E., Weitz J., Grabe N., Jaeger D. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res. 2011, 71:5670-5677.
18. Halama N., Michel S., Kloor M., Zoernig I., Pommerencke T., von Knebel Doeberitz M., Schirmacher P., Weitz J., Grabe N., Jager D. The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy. Cancer Immun. 2009, 9:1.
19. Hammond J.M., Oke P.G., Coupar B.E. A synthetic vaccinia virus promoter with enhanced early and late activity. J. Virol. Methods 1997, 66:135-138.
20. Heinemann L., Simpson G.R., Boxall A., Kottke T., Relph K.L., Vile R., Melcher A., Prestwich R., Harrington K.J., Morgan R., Pandha H.S. Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer 2011, 11:221.
21. Horwitz S.B., Horwitz M.S. Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res. 1973, 33:2834-2836.
22. Huang B., Sikorski R., Kirn D.H., Thorne S.H. Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1. Gene Ther. 2011, 18:164-172.
23. Jansen W.J., Zwart B., Hulscher S.T., Giaccone G., Pinedo H.M., Boven E. CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants. Int. J. Cancer 1997, 70:335-340.
24. Kemeny N., Tong W., Gonen M., Stockman J., Di Lauro C., Teitcher J., White P., Price C., Saltz L., Sharma S., Graham M.A. Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer. Ann. Oncol. 2002, 13:1490-1496.
25. Kerscher A.G., Chua T.C., Gasser M., Maeder U., Kunzmann V., Isbert C., Germer C.T., Pelz J.O. Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades. Br. J. Cancer 2013, 108:1432-1439.
26. Kirn D.H., Wang Y., Le Boeuf F., Bell J., Thorne S.H. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. Plos Med. 2007, 4:e353.
27. Kuijpers A.M., Mirck B., Aalbers A.G., Nienhuijs S.W., de Hingh I.H., Wiezer M.J., van Ramshorst B., van Ginkel R.J., Havenga K., Bremers A.J., de Wilt J.H., Te Velde E.A., Verwaal V.J. Cytoreduction and HIPEC in The Netherlands: nationwide long-term outcome following the Dutch protocol. Ann. Surg. Oncol. 2013, 20:4224-4230.
28. Liu G., Ding W., Liu X., Mulder K.M. c-Fos is required for TGFbeta1 production and the associated paracrine migratory effects of human colon carcinoma cells. Mol. Carcinog. 2006, 45:582-593.
29. Maitra R., Seetharam R., Tesfa L., Augustine T.A., Klampfer L., Coffey M.C., Mariadason J.M., Goel S. Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan. Oncotarget 2014, 5:2807-2819.
30. Mansfield D., Pencavel T., Kyula J.N., Zaidi S., Roulstone V., Thway K., Karapanagiotou L., Khan A.A., McLaughlin M., Touchefeu Y., Seth R., Melcher A.A., Vile R.G., Pandha H.S., Harrington K.J. Oncolytic vaccinia virus and radiotherapy in head and neck cancer. Oral Oncol. 2013, 49:108-118.
31. Marin J.J., Sanchez de Medina F., Castano B., Bujanda L., Romero M.R., Martinez-Augustin O., Moral-Avila R.D., Briz O. Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer. Drug Metab. Rev. 2012, 44:148-172.
32. McCart J.A., Mehta N., Scollard D., Reilly R.M., Carrasquillo J.A., Tang N., Deng H., Miller M., Xu H., Libutti S.K., Alexander H.R., Bartlett D.L. Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide. Mol. Ther. 2004, 10:553-561.
33. McCart J.A., Ward J.M., Lee J., Hu Y., Alexander H.R., Libutti S.K., Moss B., Bartlett D.L. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 2001, 61:8751-8757.
34. Morton C.L., Iacono L., Hyatt J.L., Taylor K.R., Cheshire P.J., Houghton P.J., Danks M.K., Stewart C.F., Potter P.M. Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice. Cancer Chemother. Pharmacol. 2005, 56:629-636.
35. Moss B. Poxviridae: the viruses and their replication. Fields' Virology 2007, Lippincott Williams & Wilkins. D. Knipe, P. Howely (Eds.).
36. Nakano K., Todo T., Zhao G., Yamaguchi K., Kuroki S., Cohen J.B., Glorioso J.C., Tanaka M. Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models. J. Gene Med. 2005, 7:638-648.
37. Ohwada S., Kobayashi I., Maemura M., Satoh Y., Ogawa T., Iino Y., Morishita Y. Interferon potentiates antiproliferative activity of CPT-11 against human colon cancer xenografts. Cancer Lett. 1996, 110:149-154.
38. Ottolino-Perry K., Diallo J.S., Lichty B.D., Bell J.C., Andrea McCart J. Intelligent design: combination therapy with oncolytic viruses. Mol. Ther. 2010, 18:251-263.
39. Ottolino-Perry K., Tang N., Head R., Ng C., Arulanandam R., Angarita F.A., Acuna S.A., Chen Y., Bell J., Dacosta R.S., McCart J.A. Tumor vascularization is critical for oncolytic vaccinia virus treatment of peritoneal carcinomatosis. Int. J. Cancer 2014, 134:717.
40. Patel M.R., Kratzke R.A. Oncolytic virus therapy for cancer: the first wave of translational clinical trials. Transl. Res. 2013, 161:355-364.
41. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer 2006, 6:789-802.
42. Satoh T., Hosokawa M., Atsumi R., Suzuki W., Hakusui H., Nagai E. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol. Pharm. Bull. 1994, 17:662-664.
43. Smith G.L., Benfield C.T., Maluquer de Motes C., Mazzon M., Ember S.W., Ferguson B.J., Sumner R.P. Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity. J. Gen. Virol. 2013, 94:2367.
44. Sobol P.T., Boudreau J.E., Stephenson K., Wan Y., Lichty B.D., Mossman K.L. Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy. Mol. Ther. 2010, 19:335-344.
45. Song C.K., Han H.D., Noh K.H., Kang T.H., Park Y.S., Kim J.H., Park E.S., Shin B.C., Kim T.W. Chemotherapy enhances CD8(+) T cell-mediated antitumor immunity induced by vaccination with vaccinia virus. Mol. Ther. 2007, 15:1558-1563.
46. Tai L.H., de Souza C.T., Belanger S., Ly L., Alkayyal A.A., Zhang J., Rintoul J.L., Ananth A.A., Lam T., Breitbach C.J., Falls T.J., Kirn D.H., Bell J.C., Makrigiannis A.P., Auer R.A. Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells. Cancer Res. 2013, 73:97-107.
47. Takakura M., Nakamura M., Kyo S., Hashimoto M., Mori N., Ikoma T., Mizumoto Y., Fujiwara T., Urata Y., Inoue M. Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination. Cancer Gene Ther. 2010, 17:11-19.
48. Wali A., Strayer D.S. Infection with vaccinia virus alters regulation of cell cycle progression. DNA Cell Biol. 1999, 18:837-843.
49. Wang E., Bussom S., Chen J., Quinn C., Bedognetti D., Lam W., Guan F., Jiang Z., Mark Y., Zhao Y., Stroncek D.F., White J., Marincola F.M., Cheng Y.C. Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment. BMC Med. Genomics 2011, 4:38. 8794-4-38.
50. Yang J.S., Nam H.J., Seo M., Han S.K., Choi Y., Nam H.G., Lee S.J., Kim S. OASIS: online application for the survival analysis of lifespan assays performed in aging research. PLoS One 2011, 6:e23525.
51. Yu Y.A., Galanis C., Woo Y., Chen N., Zhang Q., Fong Y., Szalay A.A. Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68. Mol. Cancer. Ther. 2009, 8:141-151.
52. Zaoui K., Bossow S., Grossardt C., Leber M.F., Springfeld C., Plinkert P.K., Kalle C., Ungerechts G. Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus. Cancer Gene Ther. 2012, 19:181-191.
53. Ziauddin M.F., Guo Z.S., O'Malley M.E., Austin F., Popovic P.J., Kavanagh M.A., Li J., Sathaiah M., Thirunavukarasu P., Fang B., Lee Y.J., Bartlett D.L. TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer. Gene Ther. 2010, 17:550-559.